Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14049156 | 0.78 | DGAT1 (0.50) | DGAT1ALDH1A1 | |
| SCHEMBL85598 | 0.78 | TSHR (0.40) | ALDH1A1TSHR | |
| SCHEMBL85493 | 0.76 | TSHR (0.57) | ALDH1A1TSHRCHRM1 | |
| SCHEMBL998622 | 0.76 | DGAT1 (0.61) | DGAT1ALDH1A1TSHRMEN1GAA | |
| SCHEMBL1425286 | 0.76 | DGAT1 (0.42) | DGAT1ALDH1A1TSHR | |
| SCHEMBL27897036 | 0.75 | DGAT1 (0.39) | DGAT1MEN1GAAKMT2A | |
| Hydrogen Peroxide SCHEMBL25411902 | 0.75 | DGAT1 (0.52) | DGAT1ALDH1A1TSHRMEN1GAA | |
| SCHEMBL22962550 | 0.74 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL16684201 | 0.74 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL16995758 | 0.74 | DGAT1 (0.46) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040748-B2 | 4-hydroxybutyric acid analogs | CONCERT PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-11-10 | — | — | US | disclosed |
| US-9309182-B2 | 4-hydroxybutyric acid analogs | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150210624-A1 | DEUTERATED 4-HYDROXYBUTYRIC ACID ANALOGS | CONCERT PHARMACEUTICALS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20140343119-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8759394-B2 | 4-hydroxybutyric acid analogs | CONCERT PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130012565-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | CONCERT PHARMACEUTICALS INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343119-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | DGAT1 1921/4885ALDH1A1 1583/4885TSHR 3133/4885 |
| US-10040748-B2 | 4-hydroxybutyric acid analogs | HCRTR2, HCRTR1, HTR2B | DGAT1 1921/4885ALDH1A1 1583/4885TSHR 3133/4885 |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | DGAT1 1921/4885ALDH1A1 1583/4885TSHR 3133/4885 |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | DGAT1 3866/4885ALDH1A1 3203/4885TSHR 4868/4885 |
| US-20130012565-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | DGAT1 1921/4885ALDH1A1 1583/4885TSHR 3133/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | DGAT1 3747/4885ALDH1A1 2423/4885TSHR 4863/4885 |
| US-20150210624-A1 | DEUTERATED 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HSD3B1 | DGAT1 779/4885ALDH1A1 1591/4885TSHR 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.